How to optimize administration of cefoxitin for the treatment of extended spectrum producing Enterobacteriaceae-related infection?
Cefoxitin
ESBL
PK/PD
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
23
09
2020
accepted:
13
01
2021
pubmed:
28
1
2021
medline:
9
10
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
Pharmacological and clinical data regarding cefoxitin for the treatment of ESBL-producing Enterobacteriaceae-related infections are limited. We performed a multicentric prospective cohort study to evaluate continuous/prolonged, or intermittent infusion of cefoxitin. We assessed the plasma concentration as a function of the duration of infusion and then performed a simulation of the percentage of patients who would reach the PK/PD targets, set at 100% ƒT
Identifiants
pubmed: 33502648
doi: 10.1007/s10096-021-04165-x
pii: 10.1007/s10096-021-04165-x
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cefoxitin
6OEV9DX57Y
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1393-1397Références
Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N. Engl. J. Med. 2020;382:1309–19. doi: 10.1056/NEJMoa1914433
Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S et al (2016) Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother 71:1088–1097. https://doi.org/10.1093/jac/dkv423
doi: 10.1093/jac/dkv423
pubmed: 26755492
Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E et al (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57:1488–1495. https://doi.org/10.1128/AAC.01823-12
doi: 10.1128/AAC.01823-12
pubmed: 23318796
pmcid: 3591916
Bouxom H, Fournier D, Bouiller K, Hocquet D, Bertrand X (2018) Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae? Int. J Antimicrob Agents 52:100–103. https://doi.org/10.1016/j.ijantimicag.2018.03.014
doi: 10.1016/j.ijantimicag.2018.03.014
Pilmis B, Parize P, Zahar JR, Lortholary O (2014) Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 33:1263–1265. https://doi.org/10.1007/s10096-014-2094-y
doi: 10.1007/s10096-014-2094-y
Craig WA (2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin N Am 17:479–501
doi: 10.1016/S0891-5520(03)00065-5
De Waele J, Carlier M, Hoste E, Depuydt P, Decruyenaere J, Wallis SC et al (2014) Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 80:1302–1309
pubmed: 24762706
Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL et al (2010) Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–339. https://doi.org/10.1016/j.ijantimicag.2010.06.008
doi: 10.1016/j.ijantimicag.2010.06.008
pubmed: 20685085
Roberts JA, Boots R, Rickard CM, Thomas P, Quinn J, Roberts DM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J. Antimicrob. Chemother. 2006 13;59:285–91. doi: 10.1093/jac/dkl478
Mambie A, Vuotto F, Poitrenaud D, Weyrich P, Cannesson O, Dessein R et al (2016) Cefoxitin: an alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Med Mal Infect 46:215–219. https://doi.org/10.1016/j.medmal.2016.04.008
doi: 10.1016/j.medmal.2016.04.008
pubmed: 27210283
Demonchy E, Courjon J, Ughetto E, Durand M, Risso K, Garraffo R et al (2018) Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study. Int J Antimicrob Agents 51:836–841. https://doi.org/10.1016/j.ijantimicag.2018.01.008
doi: 10.1016/j.ijantimicag.2018.01.008
pubmed: 29378342
Isla A, Trocóniz IF, de Tejada IL, Vázquez S, Canut A, López JM et al (2012) Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol 68:735–745. https://doi.org/10.1007/s00228-011-1206-1
doi: 10.1007/s00228-011-1206-1
pubmed: 22246211
EUCAST: clinical breakpoints [Internet]. [cited 2015 18];doi: http://www.eucast.org/clinical_breakpoints/
Schrogie JJ, Davies RO, Yeh KC, Rogers D, Holmes GI, Skeggs H et al (1978) Bioavailability and pharmacokinetics of cefoxitin sodium. J Antimicrob Chemother 4:69–78. https://doi.org/10.1093/jac/4.suppl_b.69
doi: 10.1093/jac/4.suppl_b.69
pubmed: 99418
Senard O, Lafaurie M, Lesprit P, Nguyen Y, Lescure X, Therby A et al (2020) Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 39:121–129. https://doi.org/10.1007/s10096-019-03701-0
doi: 10.1007/s10096-019-03701-0
Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O et al (2014) Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 58:4899–4901. https://doi.org/10.1128/AAC.02509-14
doi: 10.1128/AAC.02509-14
pubmed: 24777104
pmcid: 4135984
Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2007 1;44:357–63. doi: 10.1086/510590
McKinnon PS, Paladino JA, Schentag JJ (2008) Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345–351. https://doi.org/10.1016/j.ijantimicag.2007.12.009
doi: 10.1016/j.ijantimicag.2007.12.009
pubmed: 18313273
Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38:931–936
doi: 10.1128/AAC.38.5.931
Mouton JW, Vinks AA (2007) Continuous infusion of beta-lactams. Curr Opin Crit Care 13:598–606. https://doi.org/10.1097/MCC.0b013e3282e2a98f
doi: 10.1097/MCC.0b013e3282e2a98f
pubmed: 17762242
Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M (1989) Vink-van den Berg JC, Michel BM. Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 8:878–887. https://doi.org/10.1007/bf01963774
doi: 10.1007/bf01963774